» Articles » PMID: 39386227

Candidiasis in Breast Cancer: Tumor Progression or Not?

Abstract

is an "opportunistic fungal agent" in cancer patients that can become colonized in both mucosal and deep tissues and cause severe infections. Most evidence has shown that can enhance the progress of different cancers by several mechanisms such as generating virulence factors, participation in endogenous production of pro-inflammatory mediators, and stimulating a wide range of immune cells in the host. The main idea of this review is to describe a range of -used mechanisms that are important in candidiasis-associated malignant processes and cancer development, particularly breast cancer. This review intends to provide a detailed discussion on different regulatory mechanisms of that undoubtedly help to open new therapeutic horizons of cancer therapy in patients with fungal infection. The current therapeutic approach is not fully effective in immunocompromised and cancer patients, and further studies are required to find new products with effective antifungal properties and minimal side effects to increase the susceptibility of opportunistic fungal infections to conventional antifungal agents. So, in this situation, a special therapy should be considered to control the infection and simultaneously have the most therapeutic index on tumor patients.

References
1.
Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

2.
Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F . Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One. 2011; 6(7):e22770. PMC: 3144947. DOI: 10.1371/journal.pone.0022770. View

3.
Jimenez-Lopez C, Lorenz M . Fungal immune evasion in a model host-pathogen interaction: Candida albicans versus macrophages. PLoS Pathog. 2013; 9(11):e1003741. PMC: 3836912. DOI: 10.1371/journal.ppat.1003741. View

4.
Paulone S, Ardizzoni A, Tavanti A, Piccinelli S, Rizzato C, Lupetti A . The synthetic killer peptide KP impairs Candida albicans biofilm in vitro. PLoS One. 2017; 12(7):e0181278. PMC: 5509322. DOI: 10.1371/journal.pone.0181278. View

5.
Wakharde A, Halbandge S, Phule D, Karuppayil S . Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets. Assay Drug Dev Technol. 2018; 16(5):232-246. DOI: 10.1089/adt.2017.826. View